Drug susceptibility patterns in MDR-TB patients: Challenges for future regimen design. A cross-sectional study

Helen R. Stagg, James Brown, Elmira Ibraim, Vija Riekstiņa, Piret Viiklepp, Andra Ci'rule, Horia Cocei, Manfred Danilovitš, Gunta Dravniece, Charlotte Jackson, Peter J. White

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant tuberculosis cases, highlight the difficulties in designing universal regimen, and inform future regimen selection. Demographic and microbiological surveillance data for multidrug resistant tuberculosis cases from 2004-13 were analysed. High levels of additional resistance to currently recommended second line drugs were seen in all settings, with extensive variability between countries. Accurate drug susceptibility testing and drug susceptibility testing data are vital to inform the development of comprehensive, flexible, multidrug resistant tuberculosis guidance.

Original languageEnglish
Article numbere0142425
JournalPLoS ONE
Volume10
Issue number11
DOIs
Publication statusPublished - 1 Nov 2015

Bibliographical note

Funding Information:
The authors of this manuscript have read the journal's policy and have the following competing interests: Dr. Stagg reports personal fees and other from Otsuka Pharmaceutical, grants from National Institute for Health Research, UK, during the conduct of the study; non-financial support from Sanofi, outside the submitted work. Dr. Brown reports grants and personal fees from Otsuka Pharmaceuticals, during the conduct of the study. Dr. White reports grants and personal fees from Otsuka, during the conduct of the study. Dr. Danilovits reports personal fees and other from Otsuka Pharmaceutical, during the conduct of the study. Dr. Viiklepp reports grants from UCL Consultants Ltd, during the conduct of the study. Dr. Ibraim reports personal fees and non-financial support from Otsuka SA, during the conduct of the study; grants from German Centre for Infection Research- DZIF, outside the submitted work. Dr. Dravniece reports grants and personal fees from Otsuka, during the conduct of the study. Dr. Cocei reports grants from Otsuka SA, during the conduct of the study; grants from Romanian National Tuberculosis Programme, grants from Norway Grants, outside the submitted work. Dr. Jackson reports personal fees from Otsuka Pharmaceutical, grants from National Institute for Health Research, during the conduct of the study. Dr. Riekstina reports personal fees from Otsuka Pharmaceutical (Switzerland) during the conduct of the study. Dr. Cirule has nothing to disclose. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Publisher Copyright:
© 2015 Stagg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Fingerprint

Dive into the research topics of 'Drug susceptibility patterns in MDR-TB patients: Challenges for future regimen design. A cross-sectional study'. Together they form a unique fingerprint.

Cite this